FDA approves Novo Nordisk fast-acting insulin Fiasp
The U.S. Food and Drug Administration on Friday approved Novo Nordisk’s fast-acting insulin to treat diabetes. The product, known as Fiasp, is designed to help diabetics control post-meal spikes in blood sugar. It is already approved in Canada and Europe. Fiasp, or faster acting insulin aspart, is designed to work
Continua a leggere